349 related articles for article (PubMed ID: 27281208)
21. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models.
Shen R; Wang Q; Cheng S; Liu T; Jiang H; Zhu J; Wu Y; Wang L
Cancer Lett; 2013 Oct; 339(1):135-43. PubMed ID: 23887057
[TBL] [Abstract][Full Text] [Related]
22. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma.
Biankin AV; Kench JG; Dijkman FP; Biankin SA; Henshall SM
Pathology; 2003 Feb; 35(1):14-24. PubMed ID: 12701679
[TBL] [Abstract][Full Text] [Related]
24. JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells.
Recio-Boiles A; Ilmer M; Rhea PR; Kettlun C; Heinemann ML; Ruetering J; Vykoukal J; Alt E
Oncotarget; 2016 Mar; 7(9):9890-906. PubMed ID: 26840266
[TBL] [Abstract][Full Text] [Related]
25. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer.
Guo K; Cui J; Quan M; Xie D; Jia Z; Wei D; Wang L; Gao Y; Ma Q; Xie K
Clin Cancer Res; 2017 Feb; 23(3):687-696. PubMed ID: 27449499
[TBL] [Abstract][Full Text] [Related]
26. Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Lang M; Wang X; Wang H; Dong J; Lan C; Hao J; Huang C; Li X; Yu M; Yang Y; Yang S; Ren H
Cancer Lett; 2016 Aug; 378(2):87-96. PubMed ID: 27212442
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target.
Franses JW; Philipp J; Missios P; Bhan I; Liu A; Yashaswini C; Tai E; Zhu H; Ligorio M; Nicholson B; Tassoni EM; Desai N; Kulkarni AS; Szabolcs A; Hong TS; Liss AS; Fernandez-Del Castillo C; Ryan DP; Maheswaran S; Haber DA; Daley GQ; Ting DT
Nat Commun; 2020 Jul; 11(1):3303. PubMed ID: 32620742
[TBL] [Abstract][Full Text] [Related]
28. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
29. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
Adsay NV; Basturk O; Cheng JD; Andea AA
Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
[TBL] [Abstract][Full Text] [Related]
30. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
31. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
[TBL] [Abstract][Full Text] [Related]
32. KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.
Fujimura K; Wang H; Watson F; Klemke RL
Cancer Res; 2018 Mar; 78(6):1444-1456. PubMed ID: 29321164
[TBL] [Abstract][Full Text] [Related]
33. Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation.
Xu C; Wang Y; Tu Q; Zhang Z; Chen M; Mwangi J; Li Y; Jin Y; Zhao X; Lai R
Oncogene; 2019 Mar; 38(11):1832-1844. PubMed ID: 30356139
[TBL] [Abstract][Full Text] [Related]
34. Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma.
Hijiya N; Tsukamoto Y; Nakada C; Tung Nguyen L; Kai T; Matsuura K; Shibata K; Inomata M; Uchida T; Tokunaga A; Amada K; Shirao K; Yamada Y; Mori H; Takeuchi I; Seto M; Aoki M; Takekawa M; Moriyama M
Cancer Res; 2016 May; 76(9):2612-25. PubMed ID: 26941286
[TBL] [Abstract][Full Text] [Related]
35. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
36. Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma.
Tepel J; Kruse ML; March C; Fiedler A; Kapischke M; Ketterer T; Sipos B; Kremer B; Kalthoff H
Pancreas; 2004 Jan; 28(1):1-12. PubMed ID: 14707723
[TBL] [Abstract][Full Text] [Related]
37. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer.
Guo X; Hollander L; MacPherson D; Wang L; Velazquez H; Chang J; Safirstein R; Cha C; Gorelick F; Desir GV
Sci Rep; 2016 Mar; 6():22996. PubMed ID: 26972355
[TBL] [Abstract][Full Text] [Related]
39. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.
Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnert H; Gieseler F; Ungefroren H
Mol Cancer; 2015 Nov; 14():199. PubMed ID: 26588899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
